BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025

Reuters
2024-11-05

Nov 4 (Reuters) - Sana Biotechnology Inc :

* SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025

* SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES

* SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379

* SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION

* SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10